Human Papillomavirus and Its Testing Assays, Cervical Cancer Screening, and Vaccination

Yusheng Zhu, Yun Wang, Julie Hirschhorn, Kerry J. Welsh, Zhen Zhao, Michelle R. Davis, Sarah Feldman

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

Human papillomavirus (HPV) was found to be the causative agent for cervical cancer in the 1980s with almost 100% of cervical cancer cases testing positive for HPV. Since then, many studies have been conducted to elucidate the molecular basis of HPV, the mechanisms of carcinogenesis of the virus, and the risk factors for HPV infection. Traditionally, the Papanicolaou test was the primary screening method for cervical cancer. Because of the discovery and evolving understanding of the role of HPV in cervical dysplasia, HPV testing has been recommended as a new method for cervical cancer screening by major professional organizations including the American Cancer Society, American Society for Colposcopy and Cervical Pathology, and the American Society for Clinical Pathology. In order to detect HPV infections, many sensitive and specific HPV assays have been developed and used clinically. Different HPV assays with various principles have shown their unique advantages and limitations. In response to a clear causative relationship between high-risk HPV and cervical cancer, HPV vaccines have been developed which utilize virus-like particles to create an antibody response for the prevention of HPV infection. The vaccines have been shown in long-term follow-up studies to be effective for up to 8 years; however, how this may impact screening for vaccinated women remains uncertain. In this chapter, we will review the molecular basis of HPV, its pathogenesis, and the epidemiology of HPV infection and associated cervical cancer, discuss the methods of currently available HPV testing assays as well as recent guidelines for HPV screening, and introduce HPV vaccines as well as their impact on cervical cancer screening and treatments.

Original languageEnglish (US)
Title of host publicationAdvances in Clinical Chemistry
PublisherAcademic Press Inc.
Pages135-192
Number of pages58
DOIs
StatePublished - Jan 1 2017

Publication series

NameAdvances in Clinical Chemistry
Volume81
ISSN (Print)0065-2423

Fingerprint

Early Detection of Cancer
Uterine Cervical Neoplasms
Assays
Screening
Vaccination
Testing
Papillomavirus Vaccines
Viruses
Papillomavirus Infections
Epidemiology
Pathology
Vaccines
Antibodies
Uterine Cervical Dysplasia
Papanicolaou Test
Colposcopy
Virion
Antibody Formation
Carcinogenesis

All Science Journal Classification (ASJC) codes

  • Chemistry(all)
  • Clinical Biochemistry

Cite this

Zhu, Y., Wang, Y., Hirschhorn, J., Welsh, K. J., Zhao, Z., Davis, M. R., & Feldman, S. (2017). Human Papillomavirus and Its Testing Assays, Cervical Cancer Screening, and Vaccination. In Advances in Clinical Chemistry (pp. 135-192). (Advances in Clinical Chemistry; Vol. 81). Academic Press Inc.. https://doi.org/10.1016/bs.acc.2017.01.004
Zhu, Yusheng ; Wang, Yun ; Hirschhorn, Julie ; Welsh, Kerry J. ; Zhao, Zhen ; Davis, Michelle R. ; Feldman, Sarah. / Human Papillomavirus and Its Testing Assays, Cervical Cancer Screening, and Vaccination. Advances in Clinical Chemistry. Academic Press Inc., 2017. pp. 135-192 (Advances in Clinical Chemistry).
@inbook{0c2d13a8f41c47b7a464cd0ca01025cc,
title = "Human Papillomavirus and Its Testing Assays, Cervical Cancer Screening, and Vaccination",
abstract = "Human papillomavirus (HPV) was found to be the causative agent for cervical cancer in the 1980s with almost 100{\%} of cervical cancer cases testing positive for HPV. Since then, many studies have been conducted to elucidate the molecular basis of HPV, the mechanisms of carcinogenesis of the virus, and the risk factors for HPV infection. Traditionally, the Papanicolaou test was the primary screening method for cervical cancer. Because of the discovery and evolving understanding of the role of HPV in cervical dysplasia, HPV testing has been recommended as a new method for cervical cancer screening by major professional organizations including the American Cancer Society, American Society for Colposcopy and Cervical Pathology, and the American Society for Clinical Pathology. In order to detect HPV infections, many sensitive and specific HPV assays have been developed and used clinically. Different HPV assays with various principles have shown their unique advantages and limitations. In response to a clear causative relationship between high-risk HPV and cervical cancer, HPV vaccines have been developed which utilize virus-like particles to create an antibody response for the prevention of HPV infection. The vaccines have been shown in long-term follow-up studies to be effective for up to 8 years; however, how this may impact screening for vaccinated women remains uncertain. In this chapter, we will review the molecular basis of HPV, its pathogenesis, and the epidemiology of HPV infection and associated cervical cancer, discuss the methods of currently available HPV testing assays as well as recent guidelines for HPV screening, and introduce HPV vaccines as well as their impact on cervical cancer screening and treatments.",
author = "Yusheng Zhu and Yun Wang and Julie Hirschhorn and Welsh, {Kerry J.} and Zhen Zhao and Davis, {Michelle R.} and Sarah Feldman",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/bs.acc.2017.01.004",
language = "English (US)",
series = "Advances in Clinical Chemistry",
publisher = "Academic Press Inc.",
pages = "135--192",
booktitle = "Advances in Clinical Chemistry",
address = "United States",

}

Zhu, Y, Wang, Y, Hirschhorn, J, Welsh, KJ, Zhao, Z, Davis, MR & Feldman, S 2017, Human Papillomavirus and Its Testing Assays, Cervical Cancer Screening, and Vaccination. in Advances in Clinical Chemistry. Advances in Clinical Chemistry, vol. 81, Academic Press Inc., pp. 135-192. https://doi.org/10.1016/bs.acc.2017.01.004

Human Papillomavirus and Its Testing Assays, Cervical Cancer Screening, and Vaccination. / Zhu, Yusheng; Wang, Yun; Hirschhorn, Julie; Welsh, Kerry J.; Zhao, Zhen; Davis, Michelle R.; Feldman, Sarah.

Advances in Clinical Chemistry. Academic Press Inc., 2017. p. 135-192 (Advances in Clinical Chemistry; Vol. 81).

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Human Papillomavirus and Its Testing Assays, Cervical Cancer Screening, and Vaccination

AU - Zhu, Yusheng

AU - Wang, Yun

AU - Hirschhorn, Julie

AU - Welsh, Kerry J.

AU - Zhao, Zhen

AU - Davis, Michelle R.

AU - Feldman, Sarah

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Human papillomavirus (HPV) was found to be the causative agent for cervical cancer in the 1980s with almost 100% of cervical cancer cases testing positive for HPV. Since then, many studies have been conducted to elucidate the molecular basis of HPV, the mechanisms of carcinogenesis of the virus, and the risk factors for HPV infection. Traditionally, the Papanicolaou test was the primary screening method for cervical cancer. Because of the discovery and evolving understanding of the role of HPV in cervical dysplasia, HPV testing has been recommended as a new method for cervical cancer screening by major professional organizations including the American Cancer Society, American Society for Colposcopy and Cervical Pathology, and the American Society for Clinical Pathology. In order to detect HPV infections, many sensitive and specific HPV assays have been developed and used clinically. Different HPV assays with various principles have shown their unique advantages and limitations. In response to a clear causative relationship between high-risk HPV and cervical cancer, HPV vaccines have been developed which utilize virus-like particles to create an antibody response for the prevention of HPV infection. The vaccines have been shown in long-term follow-up studies to be effective for up to 8 years; however, how this may impact screening for vaccinated women remains uncertain. In this chapter, we will review the molecular basis of HPV, its pathogenesis, and the epidemiology of HPV infection and associated cervical cancer, discuss the methods of currently available HPV testing assays as well as recent guidelines for HPV screening, and introduce HPV vaccines as well as their impact on cervical cancer screening and treatments.

AB - Human papillomavirus (HPV) was found to be the causative agent for cervical cancer in the 1980s with almost 100% of cervical cancer cases testing positive for HPV. Since then, many studies have been conducted to elucidate the molecular basis of HPV, the mechanisms of carcinogenesis of the virus, and the risk factors for HPV infection. Traditionally, the Papanicolaou test was the primary screening method for cervical cancer. Because of the discovery and evolving understanding of the role of HPV in cervical dysplasia, HPV testing has been recommended as a new method for cervical cancer screening by major professional organizations including the American Cancer Society, American Society for Colposcopy and Cervical Pathology, and the American Society for Clinical Pathology. In order to detect HPV infections, many sensitive and specific HPV assays have been developed and used clinically. Different HPV assays with various principles have shown their unique advantages and limitations. In response to a clear causative relationship between high-risk HPV and cervical cancer, HPV vaccines have been developed which utilize virus-like particles to create an antibody response for the prevention of HPV infection. The vaccines have been shown in long-term follow-up studies to be effective for up to 8 years; however, how this may impact screening for vaccinated women remains uncertain. In this chapter, we will review the molecular basis of HPV, its pathogenesis, and the epidemiology of HPV infection and associated cervical cancer, discuss the methods of currently available HPV testing assays as well as recent guidelines for HPV screening, and introduce HPV vaccines as well as their impact on cervical cancer screening and treatments.

UR - http://www.scopus.com/inward/record.url?scp=85015438409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015438409&partnerID=8YFLogxK

U2 - 10.1016/bs.acc.2017.01.004

DO - 10.1016/bs.acc.2017.01.004

M3 - Chapter

C2 - 28629588

AN - SCOPUS:85015438409

T3 - Advances in Clinical Chemistry

SP - 135

EP - 192

BT - Advances in Clinical Chemistry

PB - Academic Press Inc.

ER -

Zhu Y, Wang Y, Hirschhorn J, Welsh KJ, Zhao Z, Davis MR et al. Human Papillomavirus and Its Testing Assays, Cervical Cancer Screening, and Vaccination. In Advances in Clinical Chemistry. Academic Press Inc. 2017. p. 135-192. (Advances in Clinical Chemistry). https://doi.org/10.1016/bs.acc.2017.01.004